Best Corrected Visual Acuity: Still the Gold Standard in Clinical Trials—But for How Long?

“As the field accelerates toward AI-enabled analytics, home-based testing, and biomarker integration, the central question becomes: How long will BCVA retain its status as the gold standard”

Best Correct Visual Acuity (BCVA) has long been a standard primary endpoint for key indications like Age-Related Macular Degeneration, Diabetic Macular Edema, and other retinal diseases. However, it is not without its limitations.

In this article with Eyes on Eyecare, Lexitas Chief Medical Officer, David Tanzer, MD, and Senior Director of Clinical and Medical Affairs, Nevin El-Nimri, OD, MS, PhD, discuss why BCVA is currently recognized as the gold standard, the known limitations of BCVA, and where the field is headed next when it comes to visual assessment.

Our Visionary Insights newsletter is published once per quarter and has thousands of subscribers. To stay in touch, subscribe today.